Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...

Two central nervous system disorder biotechs laid off employees recently. New York gene therapy startup Apertura and Boston ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, ...

The FDA on Friday approved Astellas’ treatment for a type of gastric cancer, marketed as Vyloy (zolbetuximab). The approval ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

Novartis has lost its legal challenge against the Inflation Reduction Act on Friday, making it the sixth drugmaker rejected ...

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...